Inhibrx Biosciences, Inc. (NASDAQ:INBX) operates within the highly competitive biotechnology sector, focusing on the development of protein-based therapeutics aimed at treating cancer and other serious diseases. This industry includes notable competitors such as Keros Therapeutics, Kymera Therapeutics, iTeos Therapeutics, Harmony Biosciences Holdings, and Vaxcyte, all of which are striving to innovate in the treatment space.Analyzing INBX's financial health, the company's Return on Invested Capital (ROIC) i ...